Welcome to our dedicated page for Tempus AI SEC filings (Ticker: TEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tempus AI, Inc. (NASDAQ: TEM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Tempus is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, and its filings offer insight into how it reports financial performance, manages capital, and documents material corporate events.
Investors can review Form 8-K filings where Tempus discloses items such as preliminary financial results, earnings press releases, credit agreement amendments, securities offerings, and other significant developments. For example, Tempus has used 8-K reports to furnish quarterly financial information, describe an automatic shelf registration statement and related prospectus supplement, and detail the terms of its convertible senior notes due 2030, including conversion features, redemption provisions, and associated capped call transactions.
Over time, this page will also surface Tempus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for its Diagnostics and Data and applications businesses, risk factor discussions, and management’s analysis of operations. In addition, users can expect access to ownership and insider transaction disclosures, such as Form 4 filings, when they are available from EDGAR.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings in clear language. Real-time updates from EDGAR help ensure that new TEM filings appear promptly, while AI-generated highlights can draw attention to important terms in credit agreements, securities offerings, or covenant changes. This combination allows readers to navigate Tempus’s regulatory history more efficiently, from capital structure details to ongoing financial reporting.
Tempus AI, Inc. executive Ryan Fukushima, Chief Executive Officer, Data, reported both an equity award and a related tax-sale transaction in Class A common stock. He acquired 74,993 shares at $0.00 per share as a grant/award, consisting of 8,393 fully vested restricted stock units as his 2025 bonus and 66,600 shares earned from performance-based stock units granted on August 7, 2025, after the board certified performance on February 20, 2026. Separately, he sold 9,592 shares on February 19, 2026 at a weighted average price of $59.05, in multiple trades between $58.71 and $59.38, solely to cover statutory tax withholding obligations under a mandated “sell to cover” election, not as a discretionary sale. After these transactions, he directly owned 769,347 shares, and an additional 148,808 shares were reported as indirectly owned by his spouse.
Tempus AI, Inc. Chief Financial Officer James William Rogers reported two transactions in Class A common stock. He received a grant or award of 37,496 shares at no cost, consisting of fully vested restricted stock units and earned performance-based stock units tied to previously established goals.
Rogers also sold 10,084 shares at a weighted average price of $59.05 per share to cover statutory tax withholding obligations arising from the vesting of restricted stock units. This was a mandatory "sell to cover" transaction under the company’s equity incentive plans, not a discretionary sale.
Erik Phelps reported proposed sales of Common stock in a Form 144 notice. The filing lists the sale of 3,823 shares tied to Restricted Stock Units with a transaction date of 02/19/2026. The filing also lists prior 10b5-1 sales by Erik Phelps: 3,814 shares on 02/19/2026 (amount listed 228,840.00), 6,178 shares on 02/19/2026 (amount listed 364,815.84), and 1,302 shares on 12/16/2025 (amount listed 87,780.84).
TEM insider filed Form 144 reporting an intended sale of 10,949 restricted stock units.
The filing lists prior 10b5-1 sales of 8,143 shares on 02/19/2026 for $457,310.88 and 12,874 shares on 11/24/2025 for $965,550.00. The filing identifies brokerage information dated 02/20/2026.
TEM submitted a Form 144 notifying a proposed sale of Class A Common Stock through Morgan Stanley Smith Barney LLC. The filing lists Restricted Stock Units granted on 07/14/2021 (736), 04/27/2022 (317), 04/18/2023 (317), 05/02/2024 (352), and 11/01/2024 (1,180), shown in the excerpt as securities to be sold.
Andrew Polovin reported sales of Class A Common Stock under 10b5‑1 transactions. The filing lists two sales in November 2025: 6,387 shares on 11/19/2025 for $434,708.16 and 12,874 shares on 11/24/2025 for $965,550restricted stock unit awards with grant dates and share counts: 1,549 (04/27/2022), 527 (04/18/2023), 2,107 (07/18/2023), 703 (05/02/2024), and 3,257 (11/01/2024).
Morgan Stanley Smith Barney LLC filed a Form 144 reporting sales of Class A Common Stock for related holders. The filing lists multiple sell transactions between 11/20/2025 and 01/28/2026, including repeated blocks of 133,000 and 33,250 shares on several dates with corresponding proceeds shown.
TEM submitted a Form 144 notice for proposed sales of Class A Common Stock through broker Morgan Stanley Smith Barney LLC. The filing lists restricted stock units granted on 01/03/2022 (1581 shares), 04/18/2023 (527 shares), 07/18/2023 (5377 shares), and 08/01/2024 (2107 shares). The excerpt also reports 10b5-1 sales executed in the past three months: Vanessa L. Kubo sold 5000 shares on 12/01/2025 for $378,614.93, and Ryan Fukushima sold 5000 shares on 01/05/2026 for $321,300.
TEM submitted a Form 144 notice reporting a proposed sale of 1,302 shares of Class A Common Stock under a 10b5-1 plan on 12/16/2025 for aggregate proceeds of $87,780.84.
The filing lists scheduled restricted stock units: 336 vested on 04/18/2023, 2,332 on 07/18/2023, 746 on 05/02/2024, and 2,236 on 11/01/2024. The filing also shows 172,863,470 shares outstanding as of 02/19/2026.
TEM Form 144 notice shows a reported sale of 19,966 shares of Class A Common Stock by James William Rogers on 12/11/2025 for aggregate proceeds of $1,461,438.5.
The filing also lists several restricted stock unit grants by the issuer with grant dates ranging from 04/21/2021 to 11/01/2024, each showing specific unit counts.